Healthcare / Drug Manufacturers - Specialty & GenericTokyo
$1628.00
+17.00 (+1.06%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 16%
FCF escenarios
weak_data · normalized FCF $-2.1B · quality 36.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
35/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$5.9B
P/E
29.7x
↑EV/EBITDA
9.3x
↓ROE
1.5%
↑Gross Margin
26.9%
↓Debt/Equity
0.94
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+0.1%
FCF CAGR
—
FCF margin
-6.5%
FCF / Net income
-7.22x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $32.57B · net income $294.0M · FCF $-2.12B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $32.57B | $32.57B | $30.75B | $31.56B | $32.51B |
| Net Income | $294.0M | $294.0M | $-180.0M | $339.0M | $700.0M |
| EBITDA | $1.83B | $1.83B | $1.41B | $2.10B | $2.68B |
| EPS | 81.72 | 81.72 | -50.14 | 94.07 | 194.33 |
| Gross Margin | 26.9% | 26.9% | 25.2% | 25.9% | 27.9% |
| Operating Margin | 1.9% | 1.9% | -1.6% | -0.8% | 2.5% |
| Net Margin | 0.9% | 0.9% | -0.6% | 1.1% | 2.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.94 | 0.94 | 0.92 | 0.82 | 0.80 |
| Current Ratio | 2.36 | 2.36 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-2.12B | $-2.12B | $-2.34B | $-1.93B | $1.07B |
| Returns | |||||
| ROE | 1.5% | 1.5% | -1.0% | 1.8% | 3.8% |
| Valuation | |||||
| P/E | 29.72 | 29.72 | — | 18.94 | 10.35 |
| EV/EBITDA | 9.25 | 9.25 | 9.72 | 5.30 | 3.88 |
| P/B | 0.31 | 0.31 | 0.32 | 0.35 | 0.39 |
| Growth & Yield | |||||
| Revenue Growth | 5.9% | 5.9% | -2.6% | -2.9% | — |
| EPS Growth | 263.0% | 263.0% | -153.3% | -51.6% | — |
| Dividend Yield | 3.1% | 3.1% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
20.9%
EPS terminal req.
$144.46
Spread vs growth
242.1%
5Y implied EPS CAGR
16.4%
EPS terminal req.
$174.79
Spread vs growth
246.6%
10Y implied EPS CAGR
13.2%
EPS terminal req.
$281.51
Spread vs growth
249.8%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+14.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-50.14 → 81.72
Residual
+11.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.